Roquefort Therapeutics plc
ROQ.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | -100% | – | -100% | – |
| Cost of Goods Sold | £0 | £0 | £0 | £0 |
| Gross Profit | -£0 | £0 | £0 | -£0 |
| % Margin | – | 100% | – | -1,300.4% |
| R&D Expenses | £0 | £1 | £0 | £0 |
| G&A Expenses | £1 | £2 | £1 | £0 |
| SG&A Expenses | £1 | £2 | £1 | £1 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | £0 | £0 | £0 | £0 |
| Operating Expenses | £1 | £2 | £2 | £1 |
| Operating Income | -£1 | -£2 | -£2 | -£1 |
| % Margin | – | -966.8% | – | -71,038.8% |
| Other Income/Exp. Net | -£0 | £0 | £0 | -£0 |
| Pre-Tax Income | -£1 | -£2 | -£2 | -£1 |
| Tax Expense | £0 | -£0 | -£0 | £0 |
| Net Income | -£1 | -£2 | -£2 | -£1 |
| % Margin | – | -872.3% | – | -127,598.5% |
| EPS | -0.008 | -0.014 | -0.016 | -0.037 |
| % Growth | 44.4% | 13.5% | 58% | – |
| EPS Diluted | -0.008 | -0.014 | -0.016 | -0.037 |
| Weighted Avg Shares Out | 130 | 129 | 103 | 25 |
| Weighted Avg Shares Out Dil | 130 | 129 | 103 | 25 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | £0 | £2 | £0 |
| EBITDA | -£1 | -£2 | £0 | -£0 |
| % Margin | – | -964.2% | – | -49,012.9% |